Lisata Therapeutics (CALADRIUS BIOSCIENCES)

In News

Lisata reclaims China rights to solid tumor candidate ahead of acquisition - Fierce Biotech

Fierce Biotech - Jan 27, 2026

Cancer imaging company buys Lisata for phase 2-stage solid tumor drug - Fierce Biotech

Fierce Biotech - Jan 21, 2026

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics - GlobeNewswire

GlobeNewswire - Sep 15, 2022

Bay Area's newest public company wants to cure the condition that killed André the Giant - The Business Journals

The Business Journals - Sep 17, 2026

CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug - Fierce Biotech

Fierce Biotech - Oct 09, 2025

Peripheral Artery Disease Market to Showcase Growth at a Paltry CAGR of 4% During the Study Period (2019-2032) | DelveInsight - PR Newswire

PR Newswire - Mar 29, 2023

Acute Kidney Injury Clinical Trial Pipeline Appears Robust - GlobeNewswire

GlobeNewswire - Jun 23, 2026

Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart - Fierce Biotech

Fierce Biotech - Aug 04, 2026

StockWatch: BICO CEO Addresses CFO Exit, Plunging Share Price - genengnews.com

genengnews.com - Apr 28, 2022

Global Angioplasty Balloons and Stents Market to Exhibit Substantial Growth at a CAGR of ~4% by 2030 | DelveInsight - PR Newswire

PR Newswire - May 02, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment